Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Buy” by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been assigned an average rating of “Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $27.00.

A number of equities research analysts have recently issued reports on OLMA shares. JPMorgan Chase & Co. cut their target price on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc lifted its holdings in Olema Pharmaceuticals by 6.1% in the second quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after acquiring an additional 850 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Olema Pharmaceuticals by 3.4% in the 1st quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock worth $393,000 after purchasing an additional 1,132 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Olema Pharmaceuticals by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock worth $298,000 after purchasing an additional 1,486 shares during the last quarter. ClariVest Asset Management LLC boosted its position in Olema Pharmaceuticals by 3.1% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock valued at $683,000 after purchasing an additional 1,881 shares during the period. Finally, EP Wealth Advisors LLC grew its stake in Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after buying an additional 2,407 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $9.72 on Wednesday. The company has a market capitalization of $556.96 million, a price-to-earnings ratio of -4.44 and a beta of 2.02. Olema Pharmaceuticals has a 12 month low of $7.68 and a 12 month high of $16.77. The company’s fifty day moving average price is $11.49 and its two-hundred day moving average price is $11.90.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.